DOCSLIB.ORG

Download Final Programme As

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Download Final Programme As LETTER OF INVITATION LETTER OF INVITATION WELCOME WORDS by the EANM Congress Chair EANM’20 EANM’20 On behalf of the European Association of Nuclear Medicine, it is my great honour to invite you to the 33rd Annual EANM WORLD LEADING MEETING LEADING WORLD Congress, which will take place virtually from 22 to 30 MEETING LEADING WORLD October 2020. Nuclear Medicine keeps on growing in many number of newer features are also being planned clinical areas, from diagnostic imaging to and we will have a new format for the plenary therapy: our procedures are increasingly being sessions, new top-rated oral presentation sessions incorporated into clinical practice, in a variety of and a new ‘Top Trials’ session. settings and diseases. This success is mostly related to a peculiar characteristic of our specialty, namely A further characteristic of our Congress is its the functional approach to medicine. PET imaging multidisciplinarity, and this will be emphasised works so well because of the unique functional in 2020, with a number of sessions bringing information provided to clinicians, and this feature together physicians from many specialties as well is the key to the ongoing rapid diffusion of Nuclear as specialists in radiochemistry and pharmacy, Medicine. physicists and other professionals. In addition, a dedicated track for technologists will be provided. In recent years, the status of the EANM Congress as the world-leading meeting in Nuclear Medicine If all of this still isn’t enough to motivate you to has been firmly established. The number of attend the EANM’20 Congress virtually, we are attendees in 2019 exceeded that in any previous working on providing some extra entertainment to year, with more than 6950 participants, but we make your virtual experience even more fun. This are working to make the 2020 event even bigger, will include a daily nuclear quiz, daily programme more memorable, and virtual. highlights’ announcements, games and social opportunities. EANM cares for its members, participants and patients, with safety being our primary concern as COVID-19 continues to pose a major health threat worldwide. Therefore, it was decided that it is in Stefano Fanti the best interest of the entire NM community to EANM Congress Chair 2020–2022 go virtual only. Stefano Fanti The Virtual EANM Congress will still have all the CONGRESS CHAIR 2020-2022 features that made the event successful in the past. The usual excellent tracks and sessions, from CME to joint sessions, have already been confirmed. A 4 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 5 EANM EANM BOARD & ADVISORY SPC & SESSION COUNCIL COORDINATORS EANM BOARD ADVISORY COUNCIL SCIENTIFIC PROGRAMME SESSION COORDINATORS EANM’20 COUNCIL EANM’20 The EANM Advisory Council is composed of the members of the Board and the Committee Chairs: EANM thanks all Scientific programme Council Members for EANM thanks all Session Coordinators for their huge engagement President 2019 – 2020 their great effort in composing the EANM’20 Virtual Sessions. in organizing the session details and speakers. Oyen, W.J.G (Netherlands) WORLD LEADING MEETING LEADING WORLD MEETING LEADING WORLD President Elect 2019 – 2020 Bone & Joint Committee Congress Chair Aarntzen, E. (Netherlands) Loft Jakobsen, A. (Denmark) J. Kunikowska (Poland) T. Van den Wyngaert (Belgium) Fanti, S. (Italy) Aerts, A. (Belgium) Lopci, E. (Italy) Committee Coordinator 2019 – 2020 Cardiovascular Committee Bone & Joint Committee Aide, N. (France) Luurtsema, G. (Netherlands) R. Hustinx (Belgium) H. Verberne (Netherlands) Annunziata , S. (Italy), Paycha, F. (France) Albert, N. (Germany) Lynch, T. (United Kingdom) Congress Chair 2020 – 2022 Dosimetry Committee Cardiovascular Committee S. Fanti (Italy) M.W. Konijnenberg (Netherlands) Attard, M.C. (Netherlands) Mada, M. (United Kingdom) Hyafil, F. (France), Verberne, H. (Netherlands) Education Chair 2020 – 2022 Drug Development Committee Attard, M. (The Netherlands) Mihailovic, J. (Serbia) Dosimetry Committee P. A. Erba (Italy) J. Vercouillie (France) Konijnenberg, M. (Netherlands), Eberlein, U. (Germany) Biassoni, L. (United Kingdom) Minguez Gabiña, P. (Spain) Secretary/Treasurer 2019 – 2020 Ethics Committee Drug Development Committee Camoni, L. (Italy) Morbelli, S. (Italy) W. Wadsak (Austria) W. Knapp (Germany) Vercouillie, J. (France), Smith, G. (United Kingdom) Caobelli, F. (Switzerland) Nanni, C. (Italy) Scientific Liaison Officer 2019 - 2020 Inflammation & Infection Committee Inflammation & Infection Committee M. Lassmann (Germany) A. Glaudemans (Netherlands) Catalano, O. (United States of Olianti, C. (Italy) Treglia, G. (Switzerland), Glaudemans, A. (Netherlands) America) Neuroimaging Committee Palmedo, H. (Germany) Neuroimaging Committee S. Morbelli (Italy) Cerci, J. (Brasil) Paycha, F. (France) Barthel, H. (Germany), Albert, N. (Germany) Oncology & Theranostics Committee Cunha, L. (Portugal) Petranović Ovčariček, P. (Croatia) Oncology & Theranostics Committee K. Herrmann (Germany) De Geus-Oei, L.-F. (Netherlands) Herrmann, K. (Germany), Aide, N. (France) Pietrzak, A. (Poland) Paediatrics Committee Dias, A. (Denmark) Paediatrics Committee Rep, S. (Slovenia) P. Zucchetta (Italy) Zucchetta, P. (Italy), Bar-Sever, Z. (Israel) Dickson, J. (United Kingdom) Santos, A. (Portugal) Physics Committee Physics Committee Eiber, M. (Germany) D. Visvikis (France) Saraste, A. (Finland) Dickson, J. (United Kingdom), Visvikis, D. (France) Fanti, S. (Italy) Radiation Protection Committee Schottelius, M. (Switzerland) Radiation Protection Committee S. Holm (Denmark) Fragoso Costa, P. (Germany) Sciagra, R. (Italy) Cunha, L. (Portugal), Flux, G. (United Kingdom) Radiopharmacy Committee Gabriel, M. (Austria) Semah, F. (France) Radiopharmacy Committee M. Patt (Germany) Gabriel, M. (Germany) Laverman, P. (Netherlands), Patt, M. (Germany) Smith, G. (United Kingdom) Technologist Committee Garibotto, V. (Switzerland) Technologist Committee Strobel, K. (Switzerland) A. Santos (Portugal) Santos, A. (Portugal), Camoni, L. (Italy) Goffin, K. (Belgium) Talbot, J.-N. (France) Thyroid Committee Thyroid Committee Grana, C.M. (Italy) M. Luster (Germany) Terwinghe, C. (Belgium) Hoffmann, M. (Austria), Vrachimis, A. (Cyprus) Grimm, J. (United States of America) Translational Molecular Imaging & Therapy Committee van de Giessen, E. (Netherlands) Translational Molecular Imaging & Therapy Committee F. Van Leeuwen (Netherlands) Hyafil, F. (France) van Leeuwen, F. (Netherlands), Schottelius, M. (Switzerland) Varrone, A. (Sweden) Iakovou, I. (Greece) Vercouillie, J. (France) Kobe, C. (Germany) Vidal-Sicart, S. (Spain) Konijnenberg, M. (Netherlands) Vrachimis, A. (Cyprus) Koole, M. (Belgium) Zuchetta, P. (Italy) Laverman, P. (Netherlands) 6 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 7 EANM REVIEWERS EANM REVIEWERS EANM’ 20 REVIEWERS EANM’20 Abbott, B.G. (United States of America) Beer, A. (Germany) Carrio, I. (Spain) de Swart, J. (Netherlands) EANM’20 Abgral, R. (France) Behe, M. (Switzerland) Castell Conesa, J. (Spain) Decristoforo, C. (Austria) Aerts, A. (Belgium) Beheshti, M. (Germany) Castellucci, P. (Italy) Delgado-Bolton, R.C. (Spain) Ahmadzadehfar, H. (Germany) Ben Haim, S. (Israel) Cawthorne, C. (Belgium) Deroose, C. (Belgium) WORLD LEADING MEETING LEADING WORLD Aide, N. (France) Bergström, K. (Finland) Cecchin, D. (Italy) Deuther-Conrad, W. (Germany) MEETING LEADING WORLD Ak, I. (Turkey) Bernhardt, P. (Sweden) Ceci, F. (Italy) Dickson, J. (United Kingdom) Akdemir, Ü.Ö. (Turkey) Beyer, T. (Switzerland) Cerci, J. (Brazil) Dierckx, R. (Netherlands) Aloj, L. (United Kingdom) Bilgin, B.E. (Turkey) Cermik, T.F. (Turkey ) Dierickx, L.O. (France) Altini, C. (Italy) Borbely, K. (Hungary) Chakravartty, R. (United Kingdom) Duatti, A. (Italy) Ambrosini, V. (Italy) Borgwardt, L. (Denmark) Chiaravalloti, A. (Italy) Eberlein, U. (Germany) Ametamey, S. (Switzerland) Botelho, M.F.R. (Portugal) Chiesa, C. (Italy) Eiber, M. (Germany) Anagnostopoulos, C. (Greece) Bozkurt, M.F. (Turkey) Chiti, A. (Italy) Ekmekcioglu, O. (Turkey ) Annunziata, S. (Italy) Brandt, M. (Austria) Chouin, N. (France) Elsinga, P.H. (Netherlands) Antunovic, L. (Italy) Brenner, W. (Germany) Ciappuccini, R. (France) Ertay, T. (Turkey) Armstrong, I. (United Kingdom) Brom, M. (Netherlands) Cook, G.J.R. (United Kingdom) Essler, M. (Germany) Asenbaum-Nan, S. (Austria) Brouwers, A.H. (Netherlands) Cornelissen, B. (United Kingdom) Etchebehere, E. (Brazil) Atay Kapucu, L.Ö. (Turkey) Bucerius, J. (Netherlands) Costa, G. (Portugal) Evangelista, L. (Italy) Attard, M.C. (Netherlands) Buchert, R. (Germany) Curran, D. (Ireland) Farolfi, A. (Italy) Bacher, K. (Belgium) Buckle, T. (Netherlands) Czepczyński, R. (Poland) Farsad, M. (Italy) Balkay, L. (Hungary) Burroni, L. (Italy) Da Pieve, C. (United Kingdom) Fendler, W. (Germany) Ballinger, J. (Canada) Buvat, I. (France ) Dalm, S. (Netherlands) Fernandez Lèon, A. (Spain) Balogova, S. (Slovakia) Caldarella, C. (Italy) Daou, D. (France) Ferreira, T.C. (Portugal) Bar-Sever, Z. (Israel) Camoni, L. (Italy) Darcourt, J. (France) Fischer, B.M. (Denmark) Barbet, J. (France) Cantinho-Lopes, M.G. (Portugal) De Bondt, P. (Belgium) Flotats Giralt, A. (Spain) Barthel, H. (Germany) Caobelli, F. (Switzerland) De Geus-Oei, L.-F. (Netherlands) Flux, G. (United Kingdom) Bauckneht, M. (Italy) Capa Kaya, G. (Turkey) de Jong, H. (Netherlands) Forrer, F. (Switzerland) Bax, J.J. (Netherlands) Carrilho Vaz, S. (Portugal) De Palma, D. (Italy) Fragoso Costa, P.A. (Germany) 8 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020
Load more

Recommended publications
  • Brain Imaging
    Publications · Brochures Brain Imaging A Technologist’s Guide Produced with the kind Support of Editors Fragoso Costa, Pedro (Oldenburg) Santos, Andrea (Lisbon) Vidovič, Borut (Munich) Contributors Arbizu Lostao, Javier Pagani, Marco Barthel, Henryk Payoux, Pierre Boehm, Torsten Pepe, Giovanna Calapaquí-Terán, Adriana Peștean, Claudiu Delgado-Bolton, Roberto Sabri, Osama Garibotto, Valentina Sočan, Aljaž Grmek, Marko Sousa, Eva Hackett, Elizabeth Testanera, Giorgio Hoffmann, Karl Titus Tiepolt, Solveig Law, Ian van de Giessen, Elsmarieke Lucena, Filipa Vaz, Tânia Morbelli, Silvia Werner, Peter Contents Foreword 4 Introduction 5 Andrea Santos, Pedro Fragoso Costa Chapter 1 Anatomy, Physiology and Pathology 6 Elsmarieke van de Giessen, Silvia Morbelli and Pierre Payoux Chapter 2 Tracers for Brain Imaging 12 Aljaz Socan Chapter 3 SPECT and SPECT/CT in Oncological Brain Imaging (*) 26 Elizabeth C. Hackett Chapter 4 Imaging in Oncological Brain Diseases: PET/CT 33 EANM Giorgio Testanera and Giovanna Pepe Chapter 5 Imaging in Neurological and Vascular Brain Diseases (SPECT and SPECT/CT) 54 Filipa Lucena, Eva Sousa and Tânia F. Vaz Chapter 6 Imaging in Neurological and Vascular Brain Diseases (PET/CT) 72 Ian Law, Valentina Garibotto and Marco Pagani Chapter 7 PET/CT in Radiotherapy Planning of Brain Tumours 92 Roberto Delgado-Bolton, Adriana K. Calapaquí-Terán and Javier Arbizu Chapter 8 PET/MRI for Brain Imaging 100 Peter Werner, Torsten Boehm, Solveig Tiepolt, Henryk Barthel, Karl T. Hoffmann and Osama Sabri Chapter 9 Brain Death 110 Marko Grmek Chapter 10 Health Care in Patients with Neurological Disorders 116 Claudiu Peștean Imprint 126 n accordance with the Austrian Eco-Label for printed matters.
    [Show full text]
  • Vizamyl, INN-Flutemetamol (18F)
    26 June 2014 EMA/546752/2014 Committee for Medicinal Products for Human Use (CHMP) Vizamyl flutemetamol (18F) Procedure No. EMEA/H/C/002553 Marketing authorisation holder: GE HEALTHCARE LIMITED Assessment report for an initial marketing authorisation application Assessment report as adopted by the CHMP with all commercially confidential information deleted 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2014. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 7 1.1. Submission of the dossier ...................................................................................... 7 1.2. Manufacturers ...................................................................................................... 8 1.3. Steps taken for the assessment of the product ......................................................... 8 2. Scientific discussion ................................................................................ 9 2.1. Introduction......................................................................................................... 9 2.2. Quality aspects .................................................................................................. 11 2.2.1. Introduction ...................................................................................................
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • Radiopharmaceuticals and Contrast Media – Oxford Clinical Policy
    UnitedHealthcare® Oxford Clinical Policy Radiopharmaceuticals and Contrast Media Policy Number: RADIOLOGY 034.19 T0 Effective Date: January 1, 2021 Instructions for Use Table of Contents Page Related Policies Coverage Rationale ....................................................................... 1 • Cardiology Procedures Requiring Prior Definitions .................................................................................... 10 Authorization for eviCore Healthcare Arrangement Prior Authorization Requirements .............................................. 10 • Radiation Therapy Procedures Requiring Prior Applicable Codes ........................................................................ 10 Authorization for eviCore Healthcare Arrangement Description of Services ............................................................... 13 • Radiology Procedures Requiring Prior Authorization References ................................................................................... 13 for eviCore Healthcare Arrangement Policy History/Revision Information ........................................... 14 Instructions for Use ..................................................................... 14 Coverage Rationale eviCore healthcare administers claims on behalf of Oxford Health Plans for the following services that may be billed in conjunction with radiopharmaceuticals and/or contrast media: • Radiology Services: Refer to Radiology Procedures Requiring Prior Authorization for eviCore Healthcare Arrangement for additional information.
    [Show full text]
  • 208054Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 208054Orig1s000 MEDICAL REVIEW(S) Clinical Review Phillip B. Davis, MD Priority Review 505(b)(2) NDA Axumin (18F-Fluciclovine) CLINICAL REVIEW Application Type 505 (b) (1) Application Number(s) 208054 Priority or Standard Priority Review Submit Date(s) 9/28/2015 Received Date(s) 9/28/2015 PDUFA Goal Date 5/27/2016 Division/Office DMIP/ODEIV Reviewer Name(s) Phillip B. Davis, MD Review Completion Date 2/26/2016 Established Name 18F-Fluciclovine (Proposed) Trade Name Axumin Applicant Blue Earth Diagnostics Formulation(s) Solution Dosing Regimen 10mCi via intravenous injection Applicant Proposed PET Imaging men with suspected prostate cancer recurrence. Indication(s)/Population(s) Recommendation on Approval Regulatory Action Recommended Positron emission tomography (PET) imaging of men with Indication(s)/Population(s) suspected prostate cancer recurrence. Axumin PET imaging may (if applicable) identify sites of prostate cancer. CDER Clinical Review Template 2015 Edition 1 Version date: June 25, 2015 for initial rollout (NME/original BLA reviews) Reference ID: 3897370 Clinical Review Phillip B. Davis, MD Priority Review 505(b)(2) NDA Axumin (18F-Fluciclovine) Table of Contents Glossary .................................................................................................................................. 8 1 Executive Summary .........................................................................................................10 1.1. Product Introduction ................................................................................................10
    [Show full text]
  • Initial Clinical Comparison of 18F-Florbetapir and 18F-FDG PET in Patients with Alzheimer Disease and Controls
    Journal of Nuclear Medicine, published on May 10, 2012 as doi:10.2967/jnumed.111.099606 Initial Clinical Comparison of 18F-Florbetapir and 18F-FDG PET in Patients with Alzheimer Disease and Controls Andrew B. Newberg1, Steven E. Arnold2, Nancy Wintering1, Barry W. Rovner1, and Abass Alavi2 1Thomas Jefferson University and Hospital, Philadelphia, Pennsylvania; and 2University of Pennsylvania, Philadelphia, Pennsylvania The purpose of this study was to determine how clinical inter- Alzheimer disease (AD) is a brain disorder of older pretations of the 18F-amyloid tracer florbetapir compares diagnos- adults, with symptoms of progressive decline in memory 18 tically with F-FDG PET when evaluating patients with Alzheimer and other cognitive functions. A definitive diagnosis of AD disease (AD) and controls. Methods: Nineteen patients with a clin- ical diagnosis of AD and 21 elderly controls were evaluated with can be established only by demonstrating the presence of both 18F-florbetapir and 18F-FDG PET scans. Scans were inter- abundant senile plaques and neurofibrillary tangles in post- preted together by 2 expert readers masked to any case informa- mortem brain sections (1,2). During life, most patients are tion and were assessed for tracer binding patterns consistent with diagnosed by clinical criteria that imperfectly track with AD. The criteria for interpreting the 18F-florbetapir scan as positive postmortem pathologic findings. The criteria for the diagno- for AD was the presence of binding in the cortical regions relative to sis of AD were defined by the Working Group of the Na- the cerebellum. 18F-FDG PET scans were interpreted as positive if they displayed the classic pattern of hypometabolism in the tem- tional Institute of Neurologic and Communicative Disorders poroparietal regions.
    [Show full text]
  • [18F] FACBC (Fluciclovine) PET-CT of Breast Cancer an Exploratory Study
    Journal of Nuclear Medicine, published on April 7, 2016 as doi:10.2967/jnumed.115.171389 Anti-3-[18F] FACBC (Fluciclovine) PET-CT of Breast Cancer: An Exploratory Study Funmilayo I. Tade1, Michael A. Cohen1, Toncred M. Styblo2, Oluwaseun A. Odewole1, Anna I. Holbrook1, Mary S. Newell1, Bital Savir-Baruch3, Xiaoxian Li4, Mark M. Goodman1, Jonathon A Nye1, David M. Schuster1. Author affiliations: 1. Radiology and Imaging Sciences, Emory University, Atlanta, GA, USA 2. Surgery, Emory University, Atlanta, GA, USA 3. Radiology, Loyola University Medical Center, Maywood, Illinois, USA 4. Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA Corresponding Author: David M. Schuster, MD; Division of Nuclear Medicine and Molecular Imaging, Department of Radiology and Imaging Sciences, Emory University Hospital, 1364 Clifton Road, Atlanta, GA 30322. Telephone: 404-712-4859, Fax: 404-712-4860, email: [email protected] First Author: Funmilayo Tade, MD, MPH; Research Fellow, Division of Nuclear Medicine and Molecular Imaging, Department of Radiology and Imaging Sciences, Emory University Hospital, 1364 Clifton Road, Atlanta, GA 30322. Telephone: 404-712-1348, Fax: 404-712-4860, email: [email protected] Word Count: 4,946 Grant Sponsor: Glenn Family Breast Center Grant; Winship Cancer Institute, Emory University. FLUCICLOVINE PET-CT IN BREAST CANCER The purpose of this study is to explore the uptake of the synthetic amino acid analog positron emission tomography (PET) radiotracer anti-3-[18F] FACBC (fluciclovine) in breast lesions with correlation to histologic and immunohistochemical characteristics. Methods Twelve women with breast lesions underwent 45 minute dynamic PET-CT of the thorax after intravenous administration of 366.3 ±14.8 (337.44 - 394.05) MBq of fluciclovine.
    [Show full text]
  • ACMUI Chairman, Presiding
    Official Transcript of Proceedings NUCLEAR REGULATORY COMMISSION Title: Meeting of the Advisory Committee on the Medical Uses of Isotopes Docket Number: (n/a) Location: Teleconference Date: Monday, March 30, 2020 Work Order No.: NRC-0868 Pages 1-262 NEAL R. GROSS AND CO., INC. Court Reporters and Transcribers 1323 Rhode Island Avenue, N.W. Washington, D.C. 20005 (202) 234-4433 1 UNITED STATES OF AMERICA NUCLEAR REGULATORY COMMISSION + + + + + ADVISORY COMMITTEE ON THE MEDICAL USES OF ISOTOPES + + + + + TELECONFERENCE + + + + + MONDAY, MARCH 30, 2020 + + + + + The meeting was convened by teleconference, at 9:30 a.m., Dr. Darlene F. Metter, ACMUI Chairman, presiding. MEMBERS PRESENT: DARLENE F. METTER, M.D., Chairman A. ROBERT SCHLEIPMAN, Ph.D., Vice Chairman GARY BLOOM, Member VASKEN DILSIZIAN, M.D., Member RONALD D. ENNIS, M.D., Member RICHARD L. GREEN, Member HOSSEIN JADVAR, Member MELISSA C. MARTIN, Member MICHAEL D. O'HARA, Ph.D., Member ZOUBIR OUHIB, Member NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. (202) 234-4433 WASHINGTON, D.C. 20005-3701 (202) 234-4433 2 MICHAEL SHEETZ, Member MEGAN L. SHOBER, Member HARVEY B. WOLKOV, M.D., Member DESIGNATED FEDERAL OFFICERS: CHRISTIAN EINBERG, Chief, Medical Safety and Events Assessment Branch (MSEB) LISA DIMMICK, Medical Radiation Safety Team Leader, NMSS/MSST/MSEB KELLEE JAMERSON, ACMUI Coordinator NRC STAFF PRESENT: KEVIN WILLIAMS, Deputy Director, Division of Materials Safety, Security, State, and Tribal Programs (MSST) MARYANN AYOADE, NMSS/MSST/MSEB SAID DAIBES, Ph.D., NMSS/MSST/MSEB DANIEL DIMARCO, NMSS/MSST/MSEB JASON DRAPER, NMSS/MSST/MSEB ROBIN ELLIOTT, NMSS/MSST/MSEB JENNIFER FISHER, NMSS/MSST/MSEB SARA FORSTER, NMSS/MSST/MSEB ROBERT GALLAGHAR, R-I/DNMS/MLAB ANITA GRAY, Ph.D., NMSS/MSST/SMPB VINCENT HOLAHAN, NMSS/MSST NEAL R.
    [Show full text]
  • Northern Ireland Nuclear Medicine Equipment Survey, 2017
    Northern Ireland nuclear medicine equipment survey 2017 Northern Ireland nuclear medicine equipment survey 2017 About Public Health England Public Health England exists to protect and improve the nation’s health and wellbeing and reduce health inequalities. We do this through world-leading science, knowledge and intelligence, advocacy, partnerships and the delivery of specialist public health services. We are an executive agency of the Department of Health and Social Care, and a distinct delivery organisation with operational autonomy. We provide government, local government, the NHS, Parliament, industry and the public with evidence-based professional, scientific and delivery expertise and support. Public Health England Wellington House 133-155 Waterloo Road London SE1 8UG Tel: 020 7654 8000 www.gov.uk/phe Twitter: @PHE_uk Facebook: www.facebook.com/PublicHealthEngland © Crown copyright 2019 You may re-use this information (excluding logos) free of charge in any format or medium, under the terms of the Open Government Licence v3.0. To view this licence, visit OGL. Where we have identified any third-party copyright information you will need to obtain permission from the copyright holders concerned. Published January 2019 PHE publications PHE supports the UN Sustainable Development Goals 2 Northern Ireland nuclear medicine equipment survey 2017 Contents Executive summary 4 Introduction 5 Methodology 6 Number of procedures performed 7 Procedures per scanner 8 Age of Scanners 9 Procedures reported for each organ or system 10 Procedures reported
    [Show full text]
  • October 2019 Rates Medicare Hospital Outpatient Prospective Payment System HOPPS (APC) Medicine Procedures, Radiopharmaceuticals, and Drugs
    WWW.SNMMI.ORG Final Rule 2020 Compared to October 2019 Rates Medicare Hospital Outpatient Prospective Payment System HOPPS (APC) Medicine Procedures, Radiopharmaceuticals, and Drugs October 2019 Rates CY 2020 Final Rule Updated April 2, 2020 Status Item/Code/Service OPPS Payment Status Indicator Services furnished to a hospital outpatient that are paid under a fee schedule or Not paid under OPPS. Paid by MACs under a fee schedule or payment system other than OPPS. payment system other than OPPS,* for example: A ● Separately Payable Clinical Diagnostic Laboratory Services (Not subject to Services are subject to deductible or coinsurance unless indicated otherwise. deductible or coinsurance.) D Discontinued Codes Not paid under OPPS or any other Medicare payment system. Items and Services: ● Not covered by any Medicare outpatient benefit category Not paid by Medicare when submitted on outpatient claims (any outpatient bill E1 ● Statutorily excluded by Medicare type). ● Not reasonable and necessary Items and Services: Not paid by Medicare when submitted on outpatient claims (any outpatient bill ● for which pricing information and claims data are not E2 type). available G Pass-Through Drug/ Biologicals Paid under OPPS; separate APC payment NonPass-Through Drugs and nonimplantable Biologicals, including Therapeutic Paid under OPPS; separate APC payment K Radiopharmaceuticals Paid under OPPS; payment is packaged into payment for other services. Items and Services packaged into APC rate N Therefore, there is no separate APC payment. Paid under OPPS; Addendum B displays APC assignments when services are separately payable. (1) Packaged APC payment if billed on the same claim as a HCPCS code STV-Packaged assigned status indicator “S,” “T,” or “V.” Q1 Codes (2) Composite APC payment if billed with specific combinations of services based on OPPS composite-specific payment criteria.
    [Show full text]
  • Mechanisms of Radiopharmaceutical Localization
    .::VOLUME 16, LESSON 4::. Mechanisms of Radiopharmaceutical Localization Continuing Education for Nuclear Pharmacists And Nuclear Medicine Professionals By James A. Ponto, MS, RPh, BCNP Chief Nuclear Pharmacists, University of Iowa Hospitals and Clinics and Professor (Clinical), University of Iowa Hospitals and Clinics The University of New Mexico Health Sciences Center, College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Program No. 0039-000-12-164- H04-P 2.5 Contact Hours or .25 CEUs. Initial release date: 7/19/2012 -- Intentionally left blank -- Mechanisms of Radiopharmaceutical Localization By James A. Ponto, MS, RPh, BCNP Editor, CENP Jeffrey Norenberg, MS, PharmD, BCNP, FASHP, FAPhA UNM College of Pharmacy Editorial Board Stephen Dragotakes, RPh, BCNP, FAPhA Michael Mosley, RPh, BCNP Neil Petry, RPh, MS, BCNP, FAPhA James Ponto, MS, RPh, BCNP, FAPhA Tim Quinton, PharmD, BCNP, FAPhA S. Duann Vanderslice, RPh, BCNP, FAPhA John Yuen, PharmD, BCNP Advisory Board Dave Engstrom, PharmD, BCNP Vivian Loveless, PharmD, BCNP, FAPhA Brigette Nelson, MS, PharmD, BCNP Brantley Strickland, BCNP Susan Lardner, BCNP Christine Brown, BCNP Director, CENP Administrator, CE & Web Publisher Kristina Wittstrom, MS, RPh, BCNP, FAPhA Christina Muñoz, M.A. UNM College of Pharmacy UNM College of Pharmacy While the advice and information in this publication are believed to be true and accurate at the time of press, the author(s), editors, or the publisher cannot accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, expressed or implied, with respect to the material contained herein.
    [Show full text]
  • Fluorine-18 Labeled Amino Acids for Tumor PET/CT Imaging
    www.impactjournals.com/oncotarget/ Oncotarget, 2017, Vol. 8, (No. 36), pp: 60581-60588 Review Fluorine-18 labeled amino acids for tumor PET/CT imaging Yiqiang Qi1,2,*, Xiaohui Liu1,2,*, Jun Li4, Huiqian Yao5 and Shuanghu Yuan2,3 1School of Medicine and Life Sciences, University of Jinan-Shandong Academy of Medical Sciences, Jinan, Shandong, China 2Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong Cancer Hospital affiliated to Shandong University, Jinan, Shandong, China 3Shandong Academy of Medical Sciences, Jinan, Shandong, China 4Department of Thoracic Surgery, Shandong Provincial Hospital, Jinan, Shandong, China 5Department of Surgery, Juye Coalfield Central Hospital, Heze, Shandong, China *Authors contributed equally to this work Correspondence to: Shuanghu Yuan, email: [email protected] Keywords: Fluorine-18 labeled amino acids, positron emission tomography/computed tomography (PET/CT), tumor metabolism, molecular imaging Received: May 25, 2017 Accepted: July 25, 2017 Published: August 04, 2017 Copyright: Qi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Tumor glucose metabolism and amino acid metabolism are usually enhanced, 18F-FDG for tumor glucose metabolism PET imaging has been clinically well known, but tumor amino acid metabolism PET imaging is not clinically familiar. Radiolabeled amino acids (AAs) are an important class of PET/CT tracers that target the upregulated amino acid transporters to show elevated amino acid metabolism in tumor cells. Radiolabeled amino acids were observed to have high uptake in tumor cells but low in normal tissues and inflammatory tissues.
    [Show full text]